Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

HIV Testing

Negative results Positive results
  • Confirmed HIV Negative
  • Vulnerable to HIV acquisition
  • Linked to preventative care
  • Use of HIV risk reduction tools
  • Diagnosed with HIV
  • Linked to HIV care
  • Retained in HIV Care and on ART
  • Viral Load Suppression
HIV AND STI TESTING
QUALITY CARE

HIV Prevention Tools

Information on HIV prevention tools such as PrEP, TasP, PEP, and more

About PrEP

Information on Pre-Exposure Prophylaxis, or the use of antiretroviral medications before potential HIV exposure to prevent HIV acquisition

People Who May Benefit From PrEP

Information on CDC guidance regarding who may benefit from PrEP

According to the Department of Health and Human Services (DHHS), antiretroviral therapy is recommended for all persons with HIV to reduce morbidity and mortality and to prevent the transmission of HIV to others. ART should be initiated as soon as possible.1

Baseline evaluation: Every person with HIV entering into care should have a complete medical history, physical examination, and laboratory evaluation to aid in constructing care goals and plans.2

There are several guidelines available to assist in the care of those living with HIV.3-5

The AIDSVu Service finder and HIV.gov provide information about HIV care services in your area.

Adapted from Myers J, Braunstein SL, Xia Q, et al. Redefining prevention and care: a status-neutral approach to HIV. Open Forum Infect Dis. June 2; 5(6):ofy097; 2018. doi: 10.1093/ofid/ofy097

 

ART=antiretroviral therapy; PrEP=Pre-Exposure Prophylaxis; TasP=Treatment as Prevention; PEP=Post-Exposure Prophylaxis.

References:

  1. U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Initiation of antiretroviral therapy. Updated December 18, 2019. Accessed October 13, 2021. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/initiation-antiretroviral-therapy
  2. U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Baseline evaluation. Updated May 1, 2014. Accessed October 13, 2021. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/baseline-evaluation
  3. U.S. Department of Health and Human Services. Clinical guidelines. Accessed October 13, 2021. https://clinicalinfo.hiv.gov/en/guidelines
  4. World Health Organization (WHO). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Published July 16, 2021. Accessed October 13, 2021. https://www.who.int/publications/i/item/9789240031593
  5. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel. JAMA. 2020;324(16):1651-1669.